Back to Search Start Over

Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome.

Authors :
Laish I
Levi Z
Mahajna H
Albshesh A
Horesh N
Katz E
Feldman D
Shinar N
Picard O
Yavzori M
Fudim E
Raanani P
Berger T
Goldvaser H
Beery E
Uziel O
Source :
Frontiers in oncology [Front Oncol] 2022 Sep 20; Vol. 12, pp. 962473. Date of Electronic Publication: 2022 Sep 20 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: Human telomerase reverse transcriptase (hTERT)- mRNA was shown to be elevated in exosomes derived from the sera of a variety of hematological and solid cancer patients. We aimed to evaluate its role as a diagnostic marker in patients with newly diagnosed colon cancer and in hereditary syndromes with predisposition to colon cancer.<br />Methods: hTERT -mRNA levels were determined in serum-derived exosomes from 88 patients with colon cancer, 71 Lynch-syndrome carriers with unknown active malignancies and 50 healthy controls. Data, including demographics, background diseases, clinical data regarding tumor characteristics and genetic data, were retrieved data from medical files.<br />Results: Patients with colon cancer had both higher exosomal hTERT mRNA levels and a higher proportion of patients with positive exosomal hTERT mRNA than controls (29.5% vs. 4%, respectively, P values < 0.001). Within the cancer group, patients with a metastatic disease had higher levels of telomerase mRNA than non-metastatic disease patients, and these levels correlated with CEA levels. Likewise, Lynch syndrome carriers had a higher proportion of positive exosomal hTERT mRNA than controls (21.1% vs. 4%, respectively, P value 0.008) but only a trend towards higher exosomal hTERT mRNA levels. Higher telomerase mRNA levels were not correlated with the mutated gene.<br />Conclusions: Exosomal serum hTERT -mRNA levels are associated with metastatic colon cancer and were also demonstrated in a subset of Lynch syndrome carriers. Its significance as a biomarker for developing malignancy should be elucidated.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Laish, Levi, Mahajna, Albshesh, Horesh, Katz, Feldman, Shinar, Picard, Yavzori, Fudim, Raanani, Berger, Goldvaser, Beery and Uziel.)

Details

Language :
English
ISSN :
2234-943X
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
36203446
Full Text :
https://doi.org/10.3389/fonc.2022.962473